Targets › OXA
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout May 2029.
Open in Phaseline: the race on OXA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ivan Šitum, MD | ceftazidime/avibactam Beta-lactam/beta-lactamase inhibitor - cephalosporin with avibactam inhibiting beta-lactam | SHV, OXA, KPC | Phase 4 | Severe Infection | May 2029 |
Severe Infection (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.